Glycan-Modified Peptides for Dual Inhibition of Human Immunodeficiency Virus Entry into Dendritic Cells and T Cells-Reference-Cited by-同舟云学术

Glycan-Modified Peptides for Dual Inhibition of Human Immunodeficiency Virus Entry into Dendritic Cells and T Cells

Published:2024-02-16 Issue:5 Volume:67 Page:4225-4233
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Cheng Shuihong¹²,Li Mingli¹²,Feng Yong¹²,Liu Tong¹²,He Lin³,Xu Mingyue¹²,Ma Liying³,Li Xuebing¹²^ORCID

Affiliation:

1. CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Chaoyang District, Beijing 100101, China

2. Savaid Medical School, University of Chinese Academy of Sciences, Huairou district, Beijing 101408, China

3. National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, People’s Republic of China

Funder

National Key Research and Development Program of China

National Natural Science Foundation of China

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.4c00116

Reference42 articles.

1. The Joint United Nations Programme on HIV/AIDS (UNAIDS). (2022). Global HIV & AIDS statistics ─ Fact sheet. Available at: https://www.unaids.org/en/resources/fact-sheet.

2. FDA website. Antiretroviral drugs used in the treatment of HIV infection. [(accessed on 12 April 2018)]; Available online: https://www.fda.gov/.

3. Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends

4. Highly Active Antiretroviral Therapy Decreases Mortality and Morbidity in Patients with Advanced HIV Disease

5. The end of AIDS: HIV infection as a chronic disease